Check-Cap Ltd. Ord (CHEK) 2.02 $CHEK Check-Cap to

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Check-Cap Ltd. Ord (CHEK) 2.02 $CHEK

Check-Cap to Present at the Rodman & Renshaw 18th Annual Global Investment Conference on September 13, 2016
PR Newswire - Wed Sep 07, 6:00AM CDT
Check-Cap Ltd. (Nasdaq: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today announced that Bill Densel, Chief Executive Officer, will present at the Rodman & Renshaw 18th Annual Global Investment Conference on Tuesday, September 13, 2016 at 5:30pm ET in New York City.
CHEK: 2.02 (unch)

Check-Cap Reports Second Quarter 2016 Financial Results
PR Newswire - Mon Aug 15, 3:01PM CDT
Check-Cap Ltd. (the "Company" or "Check-Cap" (NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today provided a corporate update and announced its financial results for the second quarter and six months ended June 30, 2016.
CHEK: 2.02 (unch)

Check-Cap Ltd. Announces $5.9 Million Financing
PR Newswire - Mon Aug 08, 7:26AM CDT
Check-Cap Ltd. (the "Company" or "Check-Cap" (NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today announced that it has entered into an agreement with a single health-care focused institutional investor for a registered direct placement of $5.9 million. The Securities Purchase Agreement provides for gross proceeds of $5.9 million, which is comprised of 643,614 ordinary shares, at a purchase price of $1.90 per share and 2,514,281 pre-funded warrants in lieu of ordinary shares, at a purchase price of $1.85 per warrant, which are exercisable for a nominal exercise price (approximately $0.05 per share). In the event that all warrants are exercised, the total gross proceeds to the Company for this financing would be $6.0 million.
CHEK: 2.02 (unch)

Check-Cap Announces Agreement with GE Healthcare for X-Ray Capsule Manufacturing Collaboration
PR Newswire - Thu Aug 04, 6:00AM CDT
Check-Cap Ltd. (the "Company" or "Check-Cap" (NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today announced it has entered into an agreement with GE Healthcare to develop and validate high-volume manufacturing for X-ray source production and assembly into Check-Cap's capsule. Upon successful completion, the parties may discuss collaboration on execution of a high-volume manufacturing facility and distribution of the Check-Cap system.
CHEK: 2.02 (unch)

Check-Cap Awarded $1.25 Million Grant for 2016 From Israel's Office of the Chief Scientist
PR Newswire - Tue Aug 02, 6:00AM CDT
Check-Cap Ltd. (the "Company" or "Check-Cap" (NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today announced that Israel's Office of the Chief Scientist (the "OCS" has awarded the Company a grant of NIS 4.8 million (approximately equivalent to $1.25 million based on the current exchange rate) for 2016. Charged with execution of government policy for support of R&D, the goal of the OCS is to assist in the development of technology in Israel as a means of fostering economic growth, encouraging technological innovation and entrepreneurship, leveraging Israel's scientific potential, enhancing the knowledge base of industry in Israel, stimulating high value-added R&D and encouraging R&D collaboration both nationally and internationally.
CHEK: 2.02 (unch)

A Win-Win With Check Into Cash: Cash for You and Cash for Kids
PR Newswire - Tue May 31, 11:46AM CDT
This month, don't miss Check Into Cash's Cash For Kids Facebook giveaway benefitting St. Jude Children's Research Hospital. Check Into Cash will match June's $500 giveaway prize with a $500 donation to St. Jude. St. Jude works to advance cures and prevention for pediatric catastrophic diseases, such as cancer, through research and treatment.
CHEK: 2.02 (unch)

Check-Cap Announces Preliminary Data Evaluating its Preparation-Free Colon Screening Capsule
PR Newswire - Wed May 25, 7:49AM CDT
Check-Cap Ltd. (the "Company" or "Check-Cap" (NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today announced that preliminary data from pre-clinical and clinical studies were discussed in a podium presentation entitled "A Novel Preparation-Free X-Ray Imaging Capsule for Colon Cancer Screening" during Digestive Disease Week® (DDW) 2016, taking place in San Diego from May 21-24.
CHEK: 2.02 (unch)

Check-Cap Reports First Quarter 2016 Financial Results
PR Newswire - Thu May 19, 6:00AM CDT
Check-Cap Ltd. (the "Company" or "Check-Cap" (NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today provided a corporate update and announced its financial results for the three months ended March 31, 2016.
CHEK: 2.02 (unch)

Check-Cap Announces Presentation Evaluating Ingestible Capsule for Preparation-Free Colorectal Cancer Screening at Digestive Disease Week® 2016
PR Newswire - Tue May 17, 6:00AM CDT
Check-Cap Ltd. (the "Company" or "Check-Cap" (NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today announced a podium presentation entitled "A Novel Preparation-Free X-Ray Imaging Capsule for Colon Cancer Screening" will be delivered at Digestive Disease Week® (DDW) 2016. The conference is taking place in San Diego from May 21-24.
CHEK: 2.02 (unch)

Check-Cap Announces the Publication of Preliminary Clinical Data on its Preparation-Free Colon Screening Capsule in Gut
PR Newswire - Mon Dec 14, 6:00AM CST
Check-Cap Ltd. (the "Company" or "Check-Cap" (NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today announced that data related to its clinical studies have been published in Gut, an official peer-reviewed journal of the British Society of Gastroenterology.
CHEK: 2.02 (unch)

Check-Cap CEO to Present at LD Micro Main Event on December 2, 2015
PR Newswire - Wed Nov 25, 6:00AM CST
Check-Cap Ltd. (the "Company" or "Check-Cap" (NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today announced that Bill Densel, Check-Cap's Chief Executive Officer, will present at the LD Micro 8th Annual Main Event on December 2, 2015 in Los Angeles, CA.
CHEK: 2.02 (unch)

Bradley County's Official Halloween Goblin Returns for the 2015 Block Party
Marketwired - Mon Oct 26, 8:02AM CDT
As Halloween draws near, anticipation is building in Cleveland, Tenn. around the 28th annual Halloween Block Party and the spooky appearance of Tall Betsy, Bradley County's official Halloween goblin. Tall Betsy, a 7½-foot tall goblin rumored to reside in Fort Hill Cemetery, will make her appearance from 7:30-8 p.m. The Halloween Block Party takes place from 5-10 p.m. on Saturday, October 31 in downtown Cleveland.
CHEK: 2.02 (unch)

Check-Cap Featured at the World Endoscopy Organization Colorectal Cancer Screening Committee Meeting
PR Newswire - Mon Oct 26, 6:00AM CDT
Check-Cap Ltd. (the "Company" or "Check-Cap" (NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today announced that the Check-Cap system was highlighted at the World Endoscopy Organization Colorectal Cancer Screening Committee (WEO CRC SC) Meeting which took place on October 23 in Barcelona, Spain.
CHEK: 2.02 (unch)

Check-Cap incurs lower net loss of USD48,000 for Q3 2015
M2 - Fri Oct 23, 5:43AM CDT
Medical diagnostics company Check-Cap (Nasdaq:CHEK)(Nasdaq:CHEKW) stated on Thursday its net loss of USD48,000 for the third quarter ended 30 September 2015.
CHEKW: 0.60 (-0.19), CHEK: 2.02 (unch)

Check-Cap Reports Third Quarter 2015 Financial Results
PR Newswire - Thu Oct 22, 6:00AM CDT
Check-Cap Ltd. (the "Company" or "Check-Cap" (NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today announced its financial results for the third quarter and nine months ended September 30, 2015. The Company also announced that it will hold its 2015 Annual General Meeting of Shareholders on December 1, 2015.
CHEK: 2.02 (unch)

Check-Cap Announces New Data Demonstrating Safety and Detection of Polyps in Clinical Study Evaluating Preparation-Free Colorectal Cancer Screening Capsule
PR Newswire - Tue Oct 20, 5:10AM CDT
Check-Cap Ltd. (Nasdaq: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today announced new data demonstrating safety and polyp detection from a clinical study evaluating the company's non-invasive system for preparation-free examination of the colon. Results will be presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting taking place October 16-21, 2015 and the United European Gastroenterology Week (UEGW) taking place October 24-28, 2015.
CHEK: 2.02 (unch)

Check Into Cash Launches #CheckIntoPink Campaign for Breast Cancer Awareness Month
Marketwired - Thu Oct 01, 6:01AM CDT
Check Into Cash, a national leader in alternative financial services, launches its #CheckIntoPink social campaign today to help spread knowledge about breast cancer. This is the second year in a row that Check Into Cash has participated in Breast Cancer Awareness Month to raise support for women's health. The campaign, which will run throughout October, will lead the audience to CheckIntoCash.com/GoPink, an informational page featuring tips and other educational resources.
CHEK: 2.02 (unch)

Check-Cap Announces Appointment of William Densel as Chief Executive Officer and Director
PR Newswire - Thu Aug 13, 8:30AM CDT
Check-Cap Ltd. (Nasdaq: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, announced today the appointment of William (Bill) Densel as Chief Executive Officer. The terms of Mr. Densel's engagement as Chief Executive Officer were approved at an extraordinary general meeting of shareholders held today. In addition, Check-Cap's Board of Directors elected Mr. Densel as a director to fill a vacancy on the Board, to serve in such office until the next annual general meeting of shareholders, effective as of the approval of the terms of his engagement as Chief Executive Officer by the Company's shareholders.
CHEK: 2.02 (unch)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Stavian Group Eyes AI-Driven Southeast Asia Growth

Updated Category News Views 62

AI and Infrastructure: A New Chapter for Southeast Asia What does Southeast Asia's future look like with AI steering the ship? Well, there's a fresh breeze of change blowing, and right at the heart of it stands Stavian Group. At the recently held inaugural Fortune SEA500 Summit in Ho Chi Minh City, this conglomerate threw its hat into the ring, painting a vision of growth...

Continue Reading
ASTS Faces Class Action; Investors Beware of Pitfalls

Updated Category News Views 299

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 351

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 343

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Cultural Tech Fusion: The Asia-Pacific Way Forward

Updated Category News Views 29

A High-Tech Twist on Traditional Culture You ever walk into a room and see a robot perform kung fu? I'll admit, it caught me off guard at first. But that's exactly what happened at the "Enduring Heritage, Harmonious Asia-Pacific" special exhibition in Shenzhen. With all the usual high-ranking execs and cultural bigwigs there, nobody expected a showcase where Wing Chun...

Continue Reading
FFR's OmniMind Takes Top Spot In RoboColiseum Rankings

Updated Category News Views 123

The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...

Continue Reading
CureGene's Evategrel Aims for Breakthrough in Stroke Care

Updated Category News Views 69

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 250

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 119

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 456

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading

Top 5 Most Recently Viewed Articles

Brazil Potash Secures $75 Million Equity Line for Growth

Updated Category News Views 167

Brazil Potash Secures Key Funding for Autazes Project Brazil Potash Corp. (“Brazil Potash” or the “Company”) (NYSE American: GRO), a prominent player in mineral development focused on potash mining, has recently finalized a significant agreement establishing an equity line of credit (ELOC) with Alumni Capital LP. This collaboration signals a crucial step in...

Continue Reading
AGCO Completes Major Strategic Shift Transforming Business Focus

Updated Category News Views 101

AGCO Completes Divestiture of Grain & Protein Business AGCO Corporation (NYSE: AGCO), a leading firm in agricultural machinery and precision ag technology, has finalized the sale of the majority of its Grain & Protein business to American Industrial Partners (AIP) in an all-cash deal valued at around $700 million. This significant transition emphasizes AGCO's focus on...

Continue Reading
Vincent Bouatou Takes the Helm as CTO at IDEMIA Public Security

Updated Category News Views 64

Vincent Bouatou Appointed as Chief Technology Officer With a wealth of experience in the technology sector, Vincent Bouatou has been officially announced as the Chief Technology Officer (CTO) of IDEMIA Public Security. His extensive background in driving technological innovations positions him to make significant strides in the biometric technology industry. Driving...

Continue Reading
MedX Holdings, Inc. Reaches New Heights in Q1 Revenue Growth

Updated Category News Views 171

MedX Holdings, Inc. Reports Extraordinary Q1 Revenue Gains MedX Holdings, Inc. (OTC: MEDH) is delighted to share its impressive financial results for the first quarter of 2025. With record revenue levels and strategic advancements, this milestone reflects the company's commitment to becoming a prominent player in cannabis retail, technology, and franchise development....

Continue Reading
Erste Group Upgrades WW Grainger Stock Amid Positive Outlook

Updated Category News Views 74

Erste Group upgraded WW Grainger (NYSE: GWW) from Hold to Buy back in mid-2024, showing that the desks had a new favorite. With a return on equity at a whopping 59%, Grainger's performance left many competitors in the dust, making it a must-watch stock for anyone looking to get into industrial supply chains. What's Driving the Upgrade? The reasons behind this rating shift...

Continue Reading